Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Debt to Equity (2018 - 2024)

Historic Debt to Equity for Neurocrine Biosciences (NBIX) over the last 5 years, with Q1 2024 value amounting to $0.05.

  • Neurocrine Biosciences' Debt to Equity changed N/A to $0.05 in Q1 2024 from the same period last year, while for Mar 2024 it was $0.05, marking a year-over-year change of. This contributed to the annual value of $0.08 for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q1 2024, Neurocrine Biosciences' Debt to Equity is $0.05.
  • In the past 5 years, Neurocrine Biosciences' Debt to Equity registered a high of $0.53 during Q3 2020, and its lowest value of $0.05 during Q1 2024.
  • In the last 3 years, Neurocrine Biosciences' Debt to Equity had a median value of $0.09 in 2023 and averaged $0.22.